Sign in

ARNA on NASDAQ

Arena Pharmaceuticals

Logo: Arena Pharmaceuticals, Public domain, via Wikimedia Commons5

American healthcare company

Arena Pharmaceuticals, Inc. is an American biopharmaceutical company founded in 1997 and headquartered in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas. The company's most advanced investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn's disease.3 It is part of Pfizer.1 Its shares trade on NASDAQ under the symbol ARNA.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1997Founded1

Compare with HCW Biologics Inc., Gain Therapeutics, Inc. or Lunai Bioworks Inc., or pick any stock.

  • TickerARNA on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersSan Diego1
  • Websitewww.arenapharm.com
  • Incorporated inDE6
  • Business address6154 Nancy Ridge Drive, San Diego, Ca 921216
  • Filer categoryLarge accelerated filer6
  • Legal formCorporation4
  • LEI529900CVGQMPJ3A3NI854
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressc/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 27422684

See how the biggest companies compare on our leaderboards

Arena Pharmaceuticals, Inc. is an American biopharmaceutical company founded in 1997 and headquartered in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas. The company's most advanced investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn's disease. In 2016, the company downsized and shifted its focus to developing new drugs currently being tested in clinical trials. In December 2021, Pfizer announced that it had agreed to acquire Arena for $6.7 billion in cash. In March 2022, it was announced the acquisition by Pfizer had been concluded.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-1156109.3%Operating margin8
-1141542.6%Net margin8
-83.1%Revenue growth, 20218
-91.6%Return on equity8
-$453.0MFree cash flow8

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Selling, general and admin97¢$126.2M
  • Interest3¢$4.2M

Out of $54.0K in revenue.8 The company lost money this year.

Financial statements

Revenue91011128$54.0K in 2021−100% since 2015
0$250.0M$500.0M$750.0M$1.0B2015: $13.4M$13.4M20152016: $92.2M$92.2M2016+588%2017: $21.3M$21.3M2017−77%2018: $18.0M$18.0M2018−16%2019: $806.4M$806.4M2019+4388%2020: $319.0K$319.0K2020−100%2021: $54.0K$54.0K2021−83%
Operating income91011128-$624.3M in 2021+503% since 2015
-$1.0B-$500.0M0$500.0M2015: -$103.5M-$103.5M20152016: -$5.3M-$5.3M2016−95%2017: -$92.0M-$92.0M2017+1647%2018: -$144.8M-$144.8M2018+57%2019: $482.7M$482.7M20192020: -$426.6M-$426.6M20202021: -$624.3M-$624.3M2021+46%
Net income91011128-$616.4M in 2021+471% since 2015
-$1.0B-$500.0M0$500.0M2015: -$108.0M-$108.0M20152016: -$22.5M-$22.5M2016−79%2017: -$91.4M-$91.4M2017+306%2018: -$29.4M-$29.4M2018−68%2019: $397.6M$397.6M20192020: -$404.7M-$404.7M20202021: -$616.4M-$616.4M2021+52%
Fiscal year2015201620172018201920202021
Revenue$13.4M9$92.2M10$21.3M11$18.0M12$806.4M8$319.0K8$54.0K8
Cost of revenue$8.6M13$9.3M13
Research and development$83.3M9$63.8M10$71.0M11$115.0M12$231.5M12$323.7M12
Selling, general and admin$45.3M12$77.6M8$103.2M8$126.2M8
Operating expenses$624.4M8
Operating income-$103.5M9-$5.3M10-$92.0M11-$144.8M12$482.7M8-$426.6M8-$624.3M8
Interest$6.8M9$6.5M10$6.1M11$5.7M12$4.8M8$4.5M8$4.2M8
Income before tax-$616.4M8
Income tax$09$010$011-$110.3M12$110.3M8$08$08
Net income-$108.0M9-$22.5M10-$91.4M11-$29.4M12$397.6M8-$404.7M8-$616.4M8
Earnings per share-$0.4513-$0.0913-$2.7711-$0.6312$7.998-$7.398-$10.148
Earnings per share (diluted)-$0.4513-$0.0913-$2.7711-$0.6312$7.698-$7.398-$10.148
Shares (weighted, basic)60.8M shares8
Shares (weighted, diluted)60.8M shares8

Compare Arena Pharmaceuticals with another company

Corporate structure

Arena Pharmaceuticals is part of a group headed by Pfizer. 368 entities, 64 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Arena Pharmaceuticals

  • Pfizer New York, New York, United States
    • Arena Pharmaceuticals San Diego, California, United States
    • C.P. Pharmaceuticals International C.V. New York, New York, United States
      • Ferrosan Copenhagen, Denmark
      • PF PRISM Holdings S.a r.l. (PF PRISM Holdings S.à r.l.) Subsidiary · Luxembourg, Luxembourg
      • PFIZER COMMERCIAL HOLDINGS TRAE KFT. Subsidiary · Budapest, Hungary
      • Pfizer Investment Holdings S. a r.l. (Pfizer Investment Holdings S. à r.l.) Subsidiary · Luxembourg, Luxembourg
      • PFIZER MANUFACTURING SERVICES UNLIMITED COMPANY Subsidiary · Cork, Ireland
      • PFIZER SERVICE COMPANY IRELAND UNLIMITED COMPANY Subsidiary · Dublin, Ireland
      • PFIZER SHARED SERVICES UNLIMITED COMPANY Subsidiary · Dublin, Ireland
      • PFIZER WORLDWIDE SERVICES UNLIMITED COMPANY Subsidiary · Dublin, Ireland
      • PRISM HOLDINGS B.V. Subsidiary · Capelle Aan Den Ijssel, Netherlands
    • Hospira Wilmington, Delaware, United States
      • HOSPIRA UK LIMITED Subsidiary · Royal Leamington Spa, United Kingdom
    • Pfizer AG Zurich, Switzerland
    • Pfizer Aktiebolag Stockholm, Sweden
    • Pfizer Corporation Austria Gesellschaft mbH Vienna, Austria
    • PFIZER GROUP LUXEMBOURG S.À R.L. Luxembourg, Luxembourg
      • Pfizer Deutschland GmbH Berlin, Germany
        • PFIZER MANUFACTURING DEUTSCHLAND GMBH Subsidiary · Illertissen, Germany
        • PFIZER PHARMA GMBH Subsidiary · Berlin, Germany
      • PFIZER INVESTMENT CAPITAL UNLIMITED COMPANY Subsidiary · Dublin, Ireland
      • PFIZER PHARMA PFE GMBH Subsidiary · Berlin, Germany
      • PFIZER SPAIN HOLDINGS B.V. Subsidiary · Capelle Aan Den Ijssel, Netherlands
      • PFIZER, SPOL. S R.O. Subsidiary · Vysocina, Czechia
    • PFIZER HOLDING FRANCE Paris, France
    • Pfizer Ireland Pharmaceuticals Cork, Ireland
    • PFIZER IRELAND VENTURES UNLIMITED COMPANY Cork, Ireland
    • Pfizer SA Brussels, Belgium
    • Pharmacia International B.V. Capelle aan den IJssel, Netherlands
      • Pfizer B.V. Capelle aan den IJssel, Netherlands
        • PFIZER PFE B.V. Subsidiary · Capelle Aan Den Ijssel, Netherlands
      • PFIZER MANUFACTURING BELGIUM Subsidiary · Puurs-Sint-Amands, Belgium
        • PFIZER FINANCIAL SERVICES Subsidiary · Puurs-Sint-Amands, Belgium
    • G. D. Searle & Company Subsidiary · New York City
    • Gödecke Subsidiary · Leipzig, Germany
    • Parke-Davis Subsidiary · Detroit
    • Pfizer (Canada) Subsidiary · Kirkland, Quebec, Canada
    • Pfizer UK Subsidiary · Tadworth
    • 356 Royalty Inc. Subsidiary · Delaware, United States
    • Agouron Pharmaceuticals, LLC Subsidiary · California, United States
    • AH Robins LLC Subsidiary · Delaware, United States
    • AHP HOLDINGS BV Subsidiary · Capelle Aan Den Ijssel, Netherlands
    • AHP Manufacturing B.V. Subsidiary · Capelle aan den IJssel, Netherlands
      • AHP MANUFACTURING B. V. Branch · Capelle aan den IJssel, Netherlands
    • Alpharma Pharmaceuticals LLC Subsidiary · Delaware, United States
    • Alpharma Specialty Pharma LLC Subsidiary · Delaware, United States
    • American Food Industries LLC Subsidiary · Delaware, United States
    • and 286 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (1 companies). Each entity in the chart links to its source.

What it owns

What Arena Pharmaceuticals reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$75.4M8 Dec 31, 2021$74.8M8 Dec 31, 2020+0.8%
Accumulated depreciation$56.2M8 Dec 31, 2021$52.7M8 Dec 31, 2020+6.8%
Property and equipment, net$19.1M8 Dec 31, 2021$22.1M8 Dec 31, 2020−13.4%
Operating-lease assets (leased space)$9.1M8 Dec 31, 2021

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$224.6M8 Dec 31, 2021$219.5M8 Dec 31, 2020+2.3%
Marketable securities, current$325.9M8 Dec 31, 2021$884.5M8 Dec 31, 2020−63.2%
Marketable securities, non-current$160.8M8 Dec 31, 2021$08 Dec 31, 2020

The story

Arena Pharmaceuticals Inc. is an American biopharmaceutical company founded in 1997 and headquartered in San Diego, California. Arena focused on discovering drugs that act on G protein-coupled receptors (GPCRs). The company developed technology it called Constitutively Activated Receptor Technology (CART) that identified drug leads targeting GPCRs and other classes of receptors. CART was used to identify drug leads able to act as receptor inhibitors to decrease a biological response or act as receptor activators to increase a biological response.

In January 2000, Arena entered into a collaborative agreement with Fujisawa Pharmaceutical Co. Ltd. to validate up to 13 drug targets.

In April 2000, Arena entered into a research collaboration with Eli Lilly and Company focused on the endocrine and central nervous systems.

In May 2000, Arena entered into a research collaboration with Taisho Pharmaceutical Co. focused on several GPCRs selected by Taisho in therapeutic areas of interest.

From Wikipedia’s article on Arena Pharmaceuticals, shared under CC BY-SA 4.0.7

Leadership

Who has led Arena Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jack Lief2006–2015
  2. Amit Munshi2016–2022

Chair

  1. Jack Lief2009–2014

President

  1. Jack Lief2006–2015
  2. Amit Munshi2016–2022

Chief financial officer

  1. Robert Hoffman2006–2014
  2. Kevin Robert Lind2016–2020
  3. Laurie Stelzer2020–2022
200020052010201520202025
Board members and other officers (35)

Products and brands

The company has one drug on the market, Belviq (lorcaserin), a weight-loss medication. The U.S. Food and Drug Administration (FDA) approved lorcaserin on June 27, 2012. The company committed to a sales force commitment of 200. Lorcaserin is approved for use in adults with a body mass index (BMI) of 30 or greater, which is considered obese, or adults with a BMI of 27 or greater and who have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol. However, sales of Belviq were disappointing. In 2015, the company laid off 80 workers; this was followed in July 2016 by the layoff of another 100 employees (approximately 73% of remaining workforce). In January 2017, Arena announced that it is selling Belviq to its Japanese partner, Eisai Co. Ltd., which will manufacture and market the drug; Arena will draw a royalty on global sales.

The sale completes a pivot in emphasis toward drugs still under development. Drugs in the company's pipeline includes medications designed to treat pain, ulcerative colitis and pulmonary arterial hypertension. As of September 2014, potential products that had not yet been approved by the FDA included Temanogrel (thrombotic diseases), Ralinepag (pulmonary arterial hypertension), APD334 (autoimmune disease), APD371 (pain), and Nelotanserin.

In 2018, Arena's etrasimod, a drug directed at treating ulcerative colitis (and a competitor with ozanimod from Celgene), passed phase II clinical trials successfully and moved on to phase III.

From Wikipedia’s article on Arena Pharmaceuticals, shared under CC BY-SA 4.0.7

Subsidiaries and ownership

Parent company

From Wikidata.1

Timeline

  1. Mar 11, 20228-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights53
  2. Mar 10, 20228-K Other events54
  3. Feb 23, 20228-K Results of operations55
  4. Feb 7, 20228-K Other events56
  5. Feb 2, 20228-K Shareholder vote57
  6. Jan 7, 20228-K Other events58
  7. Dec 13, 20218-K Entered a material agreement; Executive or director change; Other events59
  8. Nov 4, 20218-K Results of operations60
  9. May 11, 2016New chief executive Amit Munshi becomes CEO14
  10. Jan 3, 2006New chief executive Jack Lief becomes CEO15
  11. 1997Founded Founded1

Calendar

When it reported results

  1. Feb 23, 2022Reported quarterly or annual results55
  2. Nov 4, 2021Reported quarterly or annual results60

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

74 filings to the SEC since October 2021: 2 annual reports, 1 quarterly reports, 8 major events, 21 insider forms, 5 large holders, 37 other. The latest 20:

  1. Mar 21, 202215-12G EDGAR
  2. Mar 15, 2022EFFECT EDGAR
  3. Mar 15, 2022EFFECT EDGAR
  4. Mar 15, 2022EFFECT EDGAR
  5. Mar 15, 2022EFFECT EDGAR
  6. Mar 11, 20224 EDGAR
  7. Mar 11, 20224 EDGAR
  8. Mar 11, 20224 EDGAR
  9. Mar 11, 20224 EDGAR
  10. Mar 11, 20224 EDGAR
  11. Mar 11, 20224 EDGAR
  12. Mar 11, 20224 EDGAR
  13. Mar 11, 20224 EDGAR
  14. Mar 11, 20224 EDGAR
  15. Mar 11, 20224 EDGAR
  16. Mar 11, 20224 EDGAR
  17. Mar 11, 20224 EDGAR
  18. Mar 11, 20224 EDGAR
  19. Mar 11, 20224 EDGAR
  20. Mar 11, 20224 EDGAR

The 74 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Stakes it holds

Arena Pharmaceuticals has told the SEC it owns more than 5% of 1 company, latest first (Schedules 13D and 13G).

Members of Congress who traded it

10 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Feb 12, 2021John A. Yarmuth, HouseBuy$1,001 - $15,000Report
Nov 20, 2020Thomas R Carper, SenateBuy$1,001 - $15,000Report
Nov 5, 2020John A. Yarmuth, HouseBuy$1,001 - $15,000Report
Apr 7, 2020Kelly Loeffler, SenateSale$15,001 - $50,000Report
Feb 26, 2020Kelly Loeffler, SenatePartial sale$15,001 - $50,000Report
Feb 24, 2020Kelly Loeffler, SenatePartial sale$50,001 - $100,000Report
Feb 10, 2020Kelly Loeffler, SenatePartial sale$50,001 - $100,000Report
Feb 7, 2020Kelly Loeffler, SenatePartial sale$50,001 - $100,000Report
Feb 6, 2020Kelly Loeffler, SenatePartial sale$50,001 - $100,000Report
Feb 5, 2020Kelly Loeffler, SenatePartial sale$50,001 - $100,000Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Arena Pharmaceuticals is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARARENA PHARMACEUTICALS INC2
  • CIK0001080709
  • Filer statusLarge accelerated filer2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address6154 Nancy Ridge Drive, San Diego, CA 921212
  • Phone858-453-72002
  • Shares outstanding61,659,385 as of Feb 17, 202266
  • Public float$4.2B as of Jun 30, 202166
  • On EDGAR sinceApr 28, 20002
  • Filings1,425 in all: 4 (554), 8-K (342), SC 13G/A (91), 10-Q (65), SC 13G (38), 3 (37), S-8 POS (36), 424B5 (28)2
    All 45 form types

    10-K (22), DEF 14A (21), DEFA14A (18), S-8 (17), EFFECT (13), ARS (12), 424B3 (11), S-3 (11), SC 13D/A (11), UPLOAD (9), CORRESP (8), 5 (7), CT ORDER (6), PRE 14A (6), 4/A (5), FWP (5), POS AM (5), S-1/A (5), S-3/A (5), S-3ASR (5), S-3MEF (4), 10-K/A (3), SC 13D (3), 15-12G (2), 424B2 (2), 424B4 (2), 8-A12G (2), 8-A12G/A (2), 8-K/A (2), D (2), S-1 (2), 25-NSE (1), 3/A (1), 424A (1), DEFM14A (1), POSASR (1), PREM14A (1)

  • Latest filingsAnnual report (10-K) Feb 23, 2022
    Quarterly report (10-Q) Nov 4, 2021
    Proxy statement (DEF 14A) Apr 27, 2021
    Latest 8-K (8-K) Mar 11, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
    SEC EDGAROther events
  55. 55
  56. 56
    SEC EDGAROther events
  57. 57
  58. 58
    SEC EDGAROther events
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66